Currently, the recommended first-line treatment for patients with metastatic non-small-cell lung cancer (NSCLC) without actionable genomic alterations is immunotherapy, either alone or in combination with platinum-based chemotherapy, depending on PD-L1 expression levels [16,17]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.